Correlation Between Inozyme Pharma and Mesoblast
Can any of the company-specific risk be diversified away by investing in both Inozyme Pharma and Mesoblast at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inozyme Pharma and Mesoblast into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inozyme Pharma and Mesoblast, you can compare the effects of market volatilities on Inozyme Pharma and Mesoblast and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inozyme Pharma with a short position of Mesoblast. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inozyme Pharma and Mesoblast.
Diversification Opportunities for Inozyme Pharma and Mesoblast
-0.72 | Correlation Coefficient |
Pay attention - limited upside
The 3 months correlation between Inozyme and Mesoblast is -0.72. Overlapping area represents the amount of risk that can be diversified away by holding Inozyme Pharma and Mesoblast in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mesoblast and Inozyme Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inozyme Pharma are associated (or correlated) with Mesoblast. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mesoblast has no effect on the direction of Inozyme Pharma i.e., Inozyme Pharma and Mesoblast go up and down completely randomly.
Pair Corralation between Inozyme Pharma and Mesoblast
Given the investment horizon of 90 days Inozyme Pharma is expected to under-perform the Mesoblast. In addition to that, Inozyme Pharma is 2.42 times more volatile than Mesoblast. It trades about -0.4 of its total potential returns per unit of risk. Mesoblast is currently generating about 0.02 per unit of volatility. If you would invest 2,012 in Mesoblast on November 4, 2024 and sell it today you would earn a total of 2.00 from holding Mesoblast or generate 0.1% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Weak |
| Accuracy | 90.0% |
| Values | Daily Returns |
Inozyme Pharma vs. Mesoblast
Performance |
| Timeline |
| Inozyme Pharma |
| Mesoblast |
Inozyme Pharma and Mesoblast Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Inozyme Pharma and Mesoblast
The main advantage of trading using opposite Inozyme Pharma and Mesoblast positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inozyme Pharma position performs unexpectedly, Mesoblast can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mesoblast will offset losses from the drop in Mesoblast's long position.| Inozyme Pharma vs. Day One Biopharmaceuticals | Inozyme Pharma vs. X4 Pharmaceuticals | Inozyme Pharma vs. Acumen Pharmaceuticals | Inozyme Pharma vs. Mereo BioPharma Group |
| Mesoblast vs. Aditxt Inc | Mesoblast vs. Lipocine | Mesoblast vs. Connect Biopharma Holdings | Mesoblast vs. Acumen Pharmaceuticals |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Complementary Tools
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |